Hōʻike Hihia o ka Pane Piha Loa i ka Hepatocellular Carcinoma i nā GPC3 CAR T Cells (CT011)

He moho huahana GPC3 CAR T-cell autologous ʻo CT011 no ka mālama ʻana i ka hepatocellular carcinoma (HCC). Ua loaʻa iā CT011 ka ʻae IND mai ka NMPA i ka makahiki 2019 no ka mālama ʻana i nā maʻi me ka GPC3-positive solid tumor ʻo ia ka ʻae IND mua loa a Kina no ka CAR T-cell therapy e kūʻē i nā tumors paʻa.

ʻAukake 18, 2022, ua hoʻolaha ʻo CARsgen Therapeutics ua paʻi ʻia kahi hōʻike hihia, i kapa ʻia ʻo "Long Term Complete Response of Advanced Hepatocellular Carcinoma to Glypican-3 Specific Chimeric Antigen Receptor T-Cells plus Sorafenib, A case report", ma Frontiers in Immunology.

Ua hōʻike ʻia ka hihia i kahi maʻi kāne ʻĀsia he 60 makahiki me ka maʻi hepatitis B (HBV) e pili ana i ka HCC i hana ʻia i ke ʻoki kino i Mei 2018. I ʻAukake 2018, ua hana hou ʻia ka maʻi ʻaʻai akepaʻa a me ka metastasis pulmonary ma hope o ke ʻoki kino, a laila ua loaʻa iā ia ka transarterial chemoembolization (TACE) e mālama i nā ʻeha akepaʻa a me ka ablation interventional e mālama i nā metastases pulmonary. ʻElua mahina ma hope mai, ua holomua ʻo ia a ua kākau inoa ʻia i loko o ka hoʻokolohua lapaʻau. Ma hope o ke kākau inoa ʻana, ua hana ʻia ka maʻi i ka leukapheresis no ka hana ʻana o CAR-GPC3 T-cell. ʻEhiku lā ma hope o ka leukapheresis, ua hoʻomaka ka maʻi e loaʻa i 400 mg o sorafenib ʻelua i ka lā. Ua loaʻa i ka maʻi he 4 mau pōʻaiapuni o ka mālama ʻana i nā cell CAR-GPC3 T (CT011) a ua māhele ʻia kēlā me kēia pōʻaiapuni i ʻelua infusions. Ma mua o kēlā me kēia pōʻaiapuni o ka mālama ʻana iā CT011, ua hana ʻia ka lymphodepletion. He 4 × 10 ka huina⁹Ua hoʻokomo ʻia nā pūnaewele T CAR-GPC3.

Ua ʻae maikaʻi ʻia ka hui pū ʻana o CT011 me sorafenib. Ua loaʻa i kēia mea maʻi nā pane hapa (PR) mai ka mahina 3 a ua hoʻokō i ka CR i ka mahina 12 ma hope o ke kaʻina hana mua o ka hoʻokomo ʻana o CT011. ʻAʻohe holomua o ka puʻupuʻu no nā mahina he 36 a ua mālama i ke kūlana CR no nā mahina he 24 ma hope o ka hoʻokomo mua ʻana.

I ko mākou ʻike maikaʻi loa, ʻo kēia ka hihia mua i hōʻike ʻia me kahi CR ma hope o ka hui pū ʻana o nā pūnaewele CAR T me nā mea hoʻopaʻa tyrosine kinase. Ua hōʻike ka hopena lapaʻau e hiki i ka hui pū ʻana o ka GPC3 CAR T-cell a me Sorafenib ke lilo i ala hoʻohiki hou no nā poʻe maʻi HCC holomua GPC3+.

I kēia manawa, nui nā hoʻokolohua lapaʻau CAR-T ʻē aʻe ma Kina, a ke ʻimi nei lākou i nā maʻi. No ke kūkākūkā ʻana i nā lāʻau lapaʻau hou a me nā ʻenehana, hiki iā ʻoe ke hoʻokaʻaʻike aku i ka Beijing South Region Oncology Hospital International Department.

Helu Kelepona：4008803716

Email：myimmnet@163.com